Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia

NCT05371392 | Not Yet Recruiting

• 1 other identifier: soh-med-22-04-21
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic lymphocytic leukemia (CLL) is a clonal lymphoproliferative disorder that is characterized by heterogeneous presentation at the clinical and molecular levels. ITGA4 protein has been found to be deregulated in CLL with adverse clinical outcome. ITGA4 gene (CD49d) encodes a member of the integrin alpha chain family of proteins and is considered a negative prognosticator in CLL with aggressive course and short time to treatment. The aim of the study: is to investigate ITGA4 gene expression pattern in CLL.

Conditions

Chronic Lymphocytic Leukemia

Outcome Measures

Primary Outcomes (1)

• ITGA4 gene expression pattern in chronic lymphocytic leukemia

  Detection of ITGA4 gene expression in blood samples in patients with chronic lymphocytic leukemia, Briefly, total RNA and genomic DNA extraction from fresh peripheral blood samples by Real-time -RT-polymerase chain reaction system (RT-PCR) will be carried out. Rate of ITGA4 gene expression will be recorded.

  1 year following the startpoint of the study

Study Arms (2)

patient group

control group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

newly diagnosed patients with Chronic lymphocytic leukemia

You may qualify if:

• Patients with newly diagnosed CLL.

You may not qualify if:

• ▪ Patients previously diagnosed as CLL and received treatment before.
• Patients with other solid tumors.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag university

Sohag, Egypt

Location

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Amer Ahmed Youssif

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amer Ahmed Youssif

CONTACT

01033000406; Amer_ahmed_post@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Specialist of clinical and chemical pathology

Study Record Dates

• First Submitted: April 29, 2022
• First Posted: May 12, 2022
• Study Start: July 1, 2024
• Primary Completion: August 1, 2024
• Study Completion: October 1, 2024
• Last Updated: June 20, 2024

Record last verified: 2024-06

Locations

EG (1)